Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-01

Clinical Trial Update: PH 2 ADI-PEG 20 Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ADI-PEG 20 in Acute Myeloid Leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Polaris Group | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED